HOME >> MEDICINE >> NEWS
Aspirin reduces stroke risk in women, not men

A meta-analysis of more than 95,000 patients has shown that aspirin can significantly reduce the risk of stroke in women, but it appears to have no protective effect in men, according to a new analysis by Duke University Medical Center cardiologists.

Additionally, the researchers found that aspirin increases the risk of bleeding, or hemorrhagic, strokes in men with no effect on women. For the more common form of stroke known as ischemic stroke, in which blood flow to a portion of brain is blocked, aspirin had no effect on men but reduced the incidence in women.

The seemingly conflicting results of this study, along with the results of other studies, should lead to more intensive research into the differences between the genders when it comes to cerebrovascular disease and drugs use to prevent it, the researchers said. They emphasized that both healthy men and women who can tolerate aspirin should be taking the medication, since this analysis demonstrated its effectiveness in preventing strokes in women, and it is already known to reduce heart attacks in men.

"While we've known that aspirin is effective in preventing stroke in patients who already have cerebrovascular disease, very little is known about its abilities as a primary prevention method in otherwise healthy people," said Duke cardiology fellow Jeffrey Berger, M.D., who presented the results of his analysis Nov. 14, 2005, at the annual scientific sessions of the American Heart Association in Dallas.

"Until the advent of the Women's Health Study (WHS), clinical trials included primarily men and found that aspirin had a positive effect in reducing the risk for heart attacks, but had no effect on stroke," Berger continued. "So when the WHS found a positive effect for aspirin on stroke prevention in women, it raised the question of whether or not gender has an impact on aspirin's ability to reduce the risk of stroke."

In addition to the small numbers of women studied, the
'"/>

Contact: Richard Merritt
Merri006@mc.duke.edu
919-684-4148
Duke University Medical Center
15-Nov-2005


Page: 1 2 3

Related medicine news :

1. Aspirin use during pregnancy could reduce risk of pre-eclampsia
2. Aspirin reduces esophageal-cancer risk in people with most-aggressive form of Barretts esophagus
3. Aspirin saves lives of cancer patients suffering heart attacks, despite fears of bleeding
4. Aspirin and other NSAIDs may not reduce the risk of colorectal cancer in long-term smokers
5. Aspirin + dipyridamole better than aspirin alone to prevent circulatory problems after minor stroke
6. Aspirin shows promise in combating a common, antibiotic-induced hearing loss
7. Aspirin to prevent heart disease is beneficial in a wider range of men
8. Aspirin therapy may be safe for some survivors of brain hemorrhage
9. Aspirin reduces the risk of cardiovascular events, though effects differ between men and women
10. Aspirin reduces cardiovascular risks in men and women -- but differently
11. Aspirin may help the heart, but one in ten patients will also develop an ulcer, new research shows

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Aspirin reduces stroke risk women not men

(Date:6/19/2013)... Salt Lake City, UT (PRWEB) June 19, 2013 ... wellness companies : , In July 2013, Orriant ... optimize their participation rates, and maintain compliance with ... implemented allowing employees to receive wellness incentives if ... Orriant has announced they have been compliant with ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 As ... cancer continue to mount in courts throughout the U.S., ... Drug Administration (FDA) recently held a meeting to discuss ... as incretin mimetics. According to a June 12th ... from the makers of Januvia and similar drugs, following ...
(Date:6/19/2013)... In what is believed to be the largest follow-up ... hereditary dystonia a movement disorder that can cause ... report good success rates and lasting benefits. , Michele ... at Cedars-Sinai Medical Center,s Department of Neurology, and Ron ... at Beth Israel Deaconess Medical Center in Boston, published ...
(Date:6/19/2013)... disparities between minority and white clients in success ... these disparities vary widely from state to state. ... states there,s something amiss," says Stephan Arndt, Ph.D., ... strong racial and ethnic disparities for people in ... successfully, and those disparities are something we need ...
(Date:6/19/2013)... The Movement Disorders Center ... urologists with specialists in physical therapy, occupational therapy ... and their family members to manage diseases and ... also have the opportunity to participate in the ... disorders can be relentlessly progressive and disabling conditions, ...
Breaking Medicine News(10 mins):Health News:New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations 2Health News:New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations 3Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 2Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 3Health News:Long-term study reports deep brain stimulation effective for most common hereditary dystonia 2Health News:States vary widely on success rates for minorities in drug treatment programs 2Health News:States vary widely on success rates for minorities in drug treatment programs 3Health News:Abington Memorial Hospital’s Neurosciences Institute Opens Movement Disorders Center 2
(Date:6/19/2013)... MUMBAI, India , June 19, ... Book Bureau has recently added DrugPatentWatch ... Databases. ( http://www.bharatbook.com/drugpatentwatch-tour.pdf ) ... DrugPatentWatch provides comprehensive information on pharmaceutical, ... value-added information supports the critical business ...
(Date:6/19/2013)... --  Nektar Therapeutics (Nasdaq: NKTR ) today ... study for NKTR-181, a first-in-class, opioid analgesic molecule ... slow rate of entry is designed to reduce the euphoria ... current opioid analgesics. 1 In the study data being ... in "drug liking" and "feeling high" scores and had highly ...
(Date:6/19/2013)... June 19, 2013 BD Biosciences, a segment of ... a leading global medical technology company, today announced the launch ... latest in its line of high-performance research flow cytometers. ... multicolor analysis with the most compact footprint in its class ... a height of 30" (76.2 cm). Recognizing that space is ...
Breaking Medicine Technology:Drug Patent Watch 2Drug Patent Watch 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 2Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 4Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 5Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 6Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 7Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 8Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 9New BD Biosciences Flow Cytometry Cell Analyzer Enables Complex Multicolor Experiments in Disease Research 2
Cached News: